By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Ideas know no boundaries.
Herta Steinkellner develops tobacco plants for the fight against the Ebola.

Life Sciences Sector in Austria

More than 820 companies in the fields of biotechnology, pharmaceuticals and medical engineering generate 5.8 percent of the country’s gross domestic product (GDP) and employ a workforce of approximately 52,000 people (see www.lifescienceaustria.at).

Foreign companies also specifically rely on the research competence of Austrian bioscientists. For example, Sandoz, a subsidiary of the Novartis Group of Switzerland, has located its global competence center for biotechnology in Tyrol. Sandoz invested 100 mio. EUR in an expansion of their center. Shire’s Austrian facility is the company’s largest outside of the USA.

Companies and startups in the therapeutic, medical technology and diagnostic sectors and providers of key technologies create a dynamic environment for research. Every second biotech company is located in the hot spot of Vienna, including the Campus Vienna Biocenter, one of the leading biomedical research centers in Central and Eastern Europe. The focal points of the research being conducted include oncology, neurology, vaccines and immunology as well as precision medicine and e-health.

Sonja Polan from Life Science Austria (LISAvienna) explains the strengths of the business Location Austria.

Booming biotech scene

336 companies operate in the fields of pharmaceuticals and biotechnology. This sector is characterized by an impressive intensity of research. The approximately 100 specialized biotech firms invested the equivalent of 70 % of their total revenue in research in 2014. Primary areas of research include the efforts to win the battle against cancer and infectious diseases. The biotech sector has become an important economic factor, generating revenue of more than EUR 11.7 billion in Austria in 2014. Companies such as Boehringer Ingelheim, Eli Lilly, Takeda and Sanochemia account for the lion’s share. About one quarter of these firms operate in the core business of “red” and “white” biotechnologies. Vienna is the country’s biotech stronghold, with the Austrian capital home to every second biotech firm.

Revolutionary medical engineering

A total of 487 companies in Austria are involved in a broad spectrum of research areas, with a particular focus on electromechanical medical technology and software development. Firms producing high quality medical products include the German optics company Carl Zeiss and MED-EL, the specialist for hearing implants. The Vienna-based facility of the medical technology company Ottobock headquartered in Germany specializes in the development of high-tech prostheses. The German company Fresenius Medical Care, global market leader for dialysis therapies and products, opened its R&D center in Austria.

Total revenue in the sector was close to EUR 7.5 billion in 2014. Austria’s exceptionally good health care system, world-renowned clinics and excellent research facilities all comprise outstanding business location advantages for the medical engineering sector.

World-class cancer research

For decades, finding a cure for cancer has been one of the main goals of research in the field of health care, also in Austria. For example, the Oncotyrol competence center in Innsbruck is working with Austrian and international partners to transfer its research findings in the field of personalized cancer medicine from the laboratory to the sickbeds of patients. Boehringer Ingelheim, one of the world’s top 20 pharmaceutical companies, operates three large research and development centers around the world, one of which is located in Vienna i.e. its center for cancer and basic research at the Research Institute for Molecular Pathology (IMP). In 2017 they invested 700 mio. EUR in their R&D-facility.

More facts and figures on life sciences in Austria can be found in the Life Sciences Report Austria.

Foreign life sciences companies in Austria

  • Boehringer Ingelheim: global cancer research center
  • Shire (earlier: Baxalta BioScience): Development and production Biopharmaceuticals for rare and undertreated diseases (hematology, oncology and immunology). Austria is Baxalta’s most important location outside of the USA
  • ottobock: Research & development as well as the production of hightech prostheses for the global market
  • Sandoz (Novartis): Global competence center for biotechnology research and production of generic drugs
  • Bionorica: Research into medicinal plants focusing on analytics, development and production
  • Octapharma: Development and production of medicines from human plasma

 

 

Find out more about the life sciences location Austria in our brochure

life sciences austria
Life Sciences - Research and Invest in Austria
Download for free!
Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Connect Day

    31.05.2022, Wien, Österreich

  • AVCO Investors Breakfast

    31.05.2022/8:30-10:30, Wien, Österreich

Austria Map

Find the perfect location for your company

Thanks to a fantastic mindset, our employees at the Villach site have built up a unique expertise which helps us to further strengthen our position on the global market. We fuse high-performance manufacturing with research and development in the field of power electronics. In addition to a very good cooperation with partners and networks, a well-developed landscape of 'talent factories' ranging from higher technical colleges to universities, we as a company also value the outstanding model of research promotion which exists in Austria.

Infineon

Logo Infineon
More testimonials

news from the business location Austria

PHIOS expands to Austria

Since 2007, PHIOS has been supporting prominent companies in the implementation of particularly challenging and complex software solutions. The Liechtenstein-based company is now opening a facility in Vienna, designed to serve as the base for building up activities on the Austrian market and neighbouring countries in the CEE region.

NFT and Blockchain Hub Austria: Austria as an Attractive Location for Innovation

In the meantime, crypto assets and the blockchain technology are no longer a peripheral phenomenon. More than a decade has passed by since the release of bitcoin in the year 2009 and crypto assets and the underlying technology are continuing their advance despite the many doubters. The recent past has shown that businesspeople enjoy a favourable environment in Austria to implement their ideas relating to blockchain, NFT and the like.

More news All blog posts